Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237183 · ClinicalTrials.gov registry record · Phase 1
Iloprost in Preventing Lung Cancer in Former Smokers
A Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 2
- Study locations
NCT02237183: Completed Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
NCT02237183 is a Phase 1 study of Lung Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants, below the 5,043-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02237183, a Phase 1 study of Lung Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.
Primary Outcome
Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Descriptive statistics (mean, standard deviation \[SD\], median, max, min and range) will be provided for toxicity. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Placebo Administration
- DRUG Iloprost
Study Locations (2)
Colorado
- UCHealth University of Colorado Hospital - Aurora
- University of Colorado - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
What the finished NCT02237183 record still lists
NCT02237183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 5,043-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02237183 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02237183 about?
NCT02237183 is a clinical study titled "Iloprost in Preventing Lung Cancer in Former Smokers". This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used t...
What is the current status of trial NCT02237183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-11-05. Estimated completion is 2023-08-30.
What conditions does trial NCT02237183 study?
This clinical trial studies the following conditions: Lung Carcinoma.
What interventions are being tested in trial NCT02237183?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Placebo Administration (OTHER), Iloprost (DRUG).
Who is sponsoring clinical trial NCT02237183?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02237183 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02237183's enrollment target sits among peer trials
34 31st of 38 higher than 8 of 38 other Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
RECRUITING · Phase 1
-
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
The Rise in Robotic Atypical Segmentectomies
RECRUITING
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI